Keapstone Therapeutics keapstone.com


Public list: Pharma Startups (6570) Neuroscience Startups (947)

Keapstone Therapeutics is developing a series of small molecule activators of the Nrf2-ARE pathway for neuroprotection in Parkinson's and amyotrophic lateral sclerosis (ALS).

Keapstone Therapeutics is developing a series of small molecule activators of the Nrf2-ARE pathway for neuroprotection in Parkinson's and amyotrophic lateral sclerosis (ALS).

Company (Alive / Active)

All investors data 2 Investors

Phone: 0114 222 4330

Fax:

The Sheffield Bioincubator
40 Leavygreave Road
 Sheffield, S3 7RD
 England, United Kingdom

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Keapstone Therapeutics $3.2M Sep 26, 2018

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Keapstone Therapeutics Jobs

jobs by Indeed job search

Investors

Investor Investor Type Location Participating Rounds
See all 2 investors
There is no Board of Directors data available for this company. Please select another tab.
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)